Form 4: United Therapeutics CEO Executes Stock Option Plan

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the CEO sold the 9,500 shares in multiple transactions at weighted average prices ranging from $566.19 to $572.25.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.
• The plan remains active until the earlier of the exercise of 1,734,410 total options or December 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales are part of a pre-disclosed, systematic trading plan rather than discretionary selling.

Positives

• The transactions were executed under a pre-planned 10b5-1 program, which is a standard mechanism for corporate insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The sale represents a reduction in the CEO's direct beneficial ownership of common stock.

Risks

• Continued reliance on a large-scale 10b5-1 plan involving over 1.7 million options could lead to significant selling pressure on the stock through the end of 2026.

Future Outlook

The reporting person intends to continue selling shares under the established 10b5-1 plan until the earlier of the exhaustion of 1,734,410 options or December 31, 2026.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are common in the biotechnology sector, often used for liquidity and tax planning purposes rather than signaling a lack of confidence in company performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for C-suite executives at large-cap biotech firms like Amgen or Gilead to ensure compliance with SEC insider trading regulations.

Related Party Transactions

• The filing discloses holdings in various family trusts where the reporting person or spouse serves as trustee or beneficiary.

Stakeholder Impact

• Shareholders should note the ongoing, systematic liquidation of shares by the CEO, which is expected to continue periodically until late 2026.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, 10b5-1, Stock Options